JP6924151B2 - 免疫寛容及び非免疫寛容エラスチン様組換えペプチドならびに使用方法 - Google Patents

免疫寛容及び非免疫寛容エラスチン様組換えペプチドならびに使用方法 Download PDF

Info

Publication number
JP6924151B2
JP6924151B2 JP2017561974A JP2017561974A JP6924151B2 JP 6924151 B2 JP6924151 B2 JP 6924151B2 JP 2017561974 A JP2017561974 A JP 2017561974A JP 2017561974 A JP2017561974 A JP 2017561974A JP 6924151 B2 JP6924151 B2 JP 6924151B2
Authority
JP
Japan
Prior art keywords
gly
itep
val
seq
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017561974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521977A5 (enExample
JP2018521977A (ja
Inventor
ミンナン チェン
ミンナン チェン
ヒュン ジン チョ
ヒュン ジン チョ
ペン ワン
ペン ワン
シュユン ドン
シュユン ドン
ペン チャオ
ペン チャオ
Original Assignee
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティー オブ ユタ リサーチ ファウンデーション, ユニヴァーシティー オブ ユタ リサーチ ファウンデーション filed Critical ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
Publication of JP2018521977A publication Critical patent/JP2018521977A/ja
Publication of JP2018521977A5 publication Critical patent/JP2018521977A5/ja
Application granted granted Critical
Publication of JP6924151B2 publication Critical patent/JP6924151B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017561974A 2015-05-29 2016-05-27 免疫寛容及び非免疫寛容エラスチン様組換えペプチドならびに使用方法 Active JP6924151B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562230160P 2015-05-29 2015-05-29
US62/230,160 2015-05-29
US201662309113P 2016-03-16 2016-03-16
US62/309,113 2016-03-16
PCT/US2016/034530 WO2016196249A1 (en) 2015-05-29 2016-05-27 Immune tolerant and non-immune tolerant elastin-like recombinant peptides and methods of use

Publications (3)

Publication Number Publication Date
JP2018521977A JP2018521977A (ja) 2018-08-09
JP2018521977A5 JP2018521977A5 (enExample) 2019-07-04
JP6924151B2 true JP6924151B2 (ja) 2021-08-25

Family

ID=57441707

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017561974A Active JP6924151B2 (ja) 2015-05-29 2016-05-27 免疫寛容及び非免疫寛容エラスチン様組換えペプチドならびに使用方法

Country Status (6)

Country Link
US (1) US11957762B2 (enExample)
EP (1) EP3302531B1 (enExample)
JP (1) JP6924151B2 (enExample)
CN (1) CN107750163A (enExample)
CA (1) CA2986766A1 (enExample)
WO (1) WO2016196249A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11198722B2 (en) 2017-10-06 2021-12-14 University Of Utah Research Foundation Immune tolerant elastin-like peptide tetramer guided nanoparticles and methods of use
WO2020048996A1 (en) 2018-09-06 2020-03-12 ETH Zürich Self-assembling globular proteins and uses thereof
CN111346235A (zh) * 2018-12-20 2020-06-30 海南医学院第一附属医院 一种基于弹性靶向多肽的载药纳米颗粒及其制备方法和应用
MX2022002293A (es) * 2019-08-23 2022-06-02 Univ Utah Res Found Péptidos recombinantes inmunotolerantes similares a la elastina y métodos de uso.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5206353A (en) 1988-07-23 1993-04-27 The United States Of America As Represented By The Department Of Health And Human Services CD-4/cytotoxic gene fusions
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5981177A (en) 1995-01-25 1999-11-09 Demirjian; David C. Protein fusion method and constructs
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
WO1998022577A1 (en) 1996-11-15 1998-05-28 Maria Grazia Masucci Fusion proteins having increased half-lives
WO1998036087A1 (en) 1997-02-13 1998-08-20 American National Red Cross Immunological tolerance to hiv epitopes
US7494788B2 (en) * 2005-07-11 2009-02-24 Molecular Kinetics, Inc. Entropic bristle domain sequences and their use in recombinant protein production
US8470967B2 (en) * 2010-09-24 2013-06-25 Duke University Phase transition biopolymers and methods of use
US9114128B2 (en) * 2011-09-30 2015-08-25 Protein Genomics, Inc. Tropoelastins and uses thereof
EP3052125B1 (en) * 2013-10-01 2020-09-30 University of Mississippi Medical Center Elastin-like polypeptide coupled to therapeutic agent for delivery during pregnancy

Also Published As

Publication number Publication date
WO2016196249A1 (en) 2016-12-08
US11957762B2 (en) 2024-04-16
CA2986766A1 (en) 2016-12-08
EP3302531B1 (en) 2021-02-17
CN107750163A (zh) 2018-03-02
EP3302531A4 (en) 2019-02-20
JP2018521977A (ja) 2018-08-09
US20180289830A1 (en) 2018-10-11
EP3302531A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
Dacoba et al. Polysaccharide nanoparticles can efficiently modulate the immune response against an HIV peptide antigen
RU2748378C2 (ru) Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине
TWI823054B (zh) IL-7Rα結合化合物
Cho et al. Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriers
Moyle et al. Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines
JP7187486B2 (ja) Ｐｄ－１およびｃｔｌａ－４二重インヒビターペプチド
EP3572429A1 (en) Pd-l1 binding polypeptide or composite
WO2012099805A2 (en) Nanoparticle based immunological stimulation
WO2016146261A1 (en) Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
JP6924151B2 (ja) 免疫寛容及び非免疫寛容エラスチン様組換えペプチドならびに使用方法
ES2781085T3 (es) Mutantes de griffithsina
WO2011099684A1 (ko) Ｍｕｃ１에 대한 단일 도메인 항체
Rudra et al. Supramolecular peptide nanofibers engage mechanisms of autophagy in antigen-presenting cells
KR101579879B1 (ko) ｓｉＲＮＡ 전달을 위한 히알루론산-콜레스테롤 나노파티클 및 이를 포함하는 조성물
Zhao et al. A dual-adjuvanting strategy for peptide-based subunit vaccines against group A Streptococcus: Lipidation and polyelectrolyte complexes
Baruah et al. The emergence of nanovaccines as a new paradigm in virological vaccinology: a review
Stahl et al. Enzyme-triggered antigen release enhances cross-presentation by dendritic cells
KR101430232B1 (ko) ｓｉＲＮＡ 전달을 위한 ｐ19-ＹＳＡ 재조합 단백질 및 이를 포함하는 조성물
Hamsici et al. Drug Delivery Applications of Peptide Materials
Pho Surface Engineering of Protein Nanoparticles for Intranasal Delivery
Özcan et al. New generation peptide-based vaccine prototype
WO2010129710A1 (en) Use of rankl to induce differentiation of microfold cells (m cells)
Lin Development of gold nanoparticle-based antigen delivery platform for vaccines against HIV-1
US7314626B2 (en) Use of peptide vectors to improve the immune response to antigens
Ruseska et al. Protamine–a review on an oligonucleotide-binding peptide applied in nanopharmaceuticals including vaccines

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210730

R150 Certificate of patent or registration of utility model

Ref document number: 6924151

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250